EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Fredrik H Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Natalia G Chernova, Anna Sandberg und 6 weitere

Haematologica · 29.02.2024 · 109 (7) · 2331-2336

DOI: 10.3324/haematol.2023.284635 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Haematologica, online erschienen am 29.02.2024. Verfasst von Fredrik H Schjesvold und 17 weiteren Autor:innen. Beteiligte Einrichtung: Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norwa…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Multiple Myeloma, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaQuality of LifeAgedFemaleHumansMaleMiddle AgedDrug Resistance, NeoplasmNeoplasm Recurrence, LocalPhenylalanineRecurrenceTreatment Outcome

Substanzen

DexamethasonePhenylalanine

Autor:innen und Institutionen

  • Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com.
  • Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna.
  • Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece.
  • Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • University of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
  • Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin.

Zitieren

APA

Schjesvold, F. H., Ludwig, H., Delimpasi, S., Robak, P., Coriu, D., Tomczak, W., Pour, L., Spicka, I., Dimopoulos, M. A., Masszi, T., Chernova, N. G., Sandberg, A., Thuresson, M., Norin, S., Bakker, N. A., Mateos, M. V., Richardson, P. G., & Sonneveld, P. (2024). Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica, 109(7), 2331-2336. https://doi.org/10.3324/haematol.2023.284635

Vancouver

Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, et al. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024;109(7):2331-2336. doi:10.3324/haematol.2023.284635

BibTeX
@article{Schjesvold2024,
  author = {Schjesvold, Fredrik H and Ludwig, Heinz and Delimpasi, Sossana and Robak, Pawel and Coriu, Daniel and Tomczak, Waldemar and Pour, Ludek and Spicka, Ivan and Dimopoulos, Meletios-Athanasios and Masszi, Tamas and Chernova, Natalia G and Sandberg, Anna and Thuresson, Marcus and Norin, Stefan and Bakker, Nicolaas A and Mateos, Maria-Victoria and Richardson, Paul G and Sonneveld, Pieter},
  title = {Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study},
  journal = {Haematologica},
  year = {2024},
  volume = {109},
  number = {7},
  pages = {2331--2336},
  doi = {10.3324/haematol.2023.284635}
}
Kostenlos starten →